Publication:
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.

Loading...
Thumbnail Image

Date

2017

Authors

Sartor, O
Heinrich, D
Mariados, N
Mendez Vidal, M J
Keizman, D
Thellenberg Karlsson, C
Peer, A
Procopio, G
Frank, S J
Pulkkanen, K

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Six radium-223 injections at 4-week intervals is indicated for patients with castration-resistant prostate cancer and symptomatic bone metastases. However, patients usually develop disease progression after initial treatment. This prospective phase I/II study assessed re-treatment safety and efficacy of up to six additional radium-223 injections. Patients had castration-resistant prostate cancer and bone metastases and six initial radium-223 injections with no on-treatment bone progression; all had subsequent radiologic or clinical progression. Concomitant agents were allowed at investigator discretion, excluding chemotherapy and initiation of new abiraterone or enzalutamide. The primary endpoint was safety; additional exploratory endpoints included time to radiographic bone progression, time to total alkaline phosphatase and prostate-specific antigen progression, radiographic progression-free survival, overall survival, time to first symptomatic skeletal event (SSE), SSE-free survival, and time to pain progression. Among 44 patients, 29 (66%) received all six re-treatment injections. Median time from end of initial radium-223 treatment was 6 months. Forty-one (93%) reported ≥1 treatment-emergent adverse event. No grade 4-5 hematologic treatment-emergent adverse events occurred. Only one (2%) patient had radiographic bone progression; eight (18%) had radiographic soft tissue tumor progression (three lymph node and five visceral metastases). Median times to total alkaline phosphatase and prostate-specific antigen progression were not reached and 2.2 months, respectively. Median radiographic progression-free survival was 9.9 months (12.8-month maximum follow-up). Five (11%) patients died and eight (18%) experienced first SSEs. Median overall survival, time to first SSE, and SSE-free survival were not reached. Five (14%) of 36 evaluable patients (baseline worst pain score ≤7) had pain progression. After 2 years of follow-up, 28 (64%) patients died, and the median overall survival was 24.4 months. Re-treatment with a second course of six radium-223 injections after disease progression is well tolerated, with minimal hematologic toxicity and low radiographic bone progression rates in this small study with limited follow-up. Favorable safety and early effects on disease progression indicate that radium-223 re-treatment is feasible and warrants further evaluation in larger prospective trials.

Description

MeSH Terms

Aged
Aged, 80 and over
Alkaline phosphatase
Bone neoplasms
Humans
Kallikreins
Male
Middle aged
Prospective studies
Prostate-specific antigen
Prostatic neoplasms, castration-resistant
Radium
Re-irradiation

DeCS Terms

Antígeno prostático específico
Calicreínas
Fosfatasa alcalina
Neoplasias de la próstata resistentes a la castración
Neoplasias óseas
Radio
Reirradiación

CIE Terms

Keywords

Bone metastases, Injections, Prostate, Radium-223, Re-treatment, Safety

Citation

Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, Thellenberg Karlsson C, et al. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Ann Oncol. 2017 Oct 1;28(10):2464-2471